These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Gain-of-Function Polymorphisms in Human Inflammasomes: Implications for Cystic Fibrosis. Jeansonne D; Jeyaseelan S Am J Respir Cell Mol Biol; 2021 Aug; 65(2):126-127. PubMed ID: 34033526 [No Abstract] [Full Text] [Related]
64. In silico search for modifier genes associated with pancreatic and liver disease in Cystic Fibrosis. Trouvé P; Génin E; Férec C PLoS One; 2017; 12(3):e0173822. PubMed ID: 28339466 [TBL] [Abstract][Full Text] [Related]
65. HLA determinants in families with more than one member with cystic fibrosis. Herrod HG; Amos DB; Spock A J Pediatr; 1979 Apr; 94(4):676. PubMed ID: 85700 [No Abstract] [Full Text] [Related]
66. Treatment complexity in cystic fibrosis (CF): An increasing multifaceted challenge. Phan H Pediatr Pulmonol; 2018 Sep; 53(9):1174-1176. PubMed ID: 29856505 [No Abstract] [Full Text] [Related]
67. Third component of complement in cystic fibrosis. Holzhauer RJ; Van Ess JD; Schwartz RH Am J Hum Genet; 1976 Nov; 28(6):602-6. PubMed ID: 1008063 [TBL] [Abstract][Full Text] [Related]
68. Cystic fibrosis of pancreas and nephrotic syndrome: a rare association. Kelekçi S; Karabel M; Ece A; Sen V; Güneş A; Yolbaş I; Sahin C Korean J Pediatr; 2013 Oct; 56(10):456-8. PubMed ID: 24244215 [TBL] [Abstract][Full Text] [Related]
69. [Human leukocyte antigen (HLA) system in ophthalmology]. Lapp T; Reinhold D; Böhringer D; Reinhard T Ophthalmologe; 2013 Sep; 110(9):849-61. PubMed ID: 23695291 [TBL] [Abstract][Full Text] [Related]
70. [The physiological role of the HLA system and the population aspects]. Khaitov RM; Boldyreva MN; Alekseev LP Ross Fiziol Zh Im I M Sechenova; 2009 Mar; 95(3):235-49. PubMed ID: 19449780 [TBL] [Abstract][Full Text] [Related]
71. Severity of chest disease in CF patients in relation to their genotypes. Packe GE; Miedzybrodzka ZH; Dean JC J Med Genet; 1993 Aug; 30(8):709. PubMed ID: 8411065 [No Abstract] [Full Text] [Related]
72. Cystic fibrosis serum effect on the short circuit current of rat jejunum. Tucker RD; Gibbs GE; Christensen MB Pediatr Res; 1979 Dec; 13(12):1371-4. PubMed ID: 523197 [TBL] [Abstract][Full Text] [Related]
74. Expansion and uncertainty: cystic fibrosis, classification and genetics. Hedgecoe AM Sociol Health Illn; 2003 Jan; 25(1):50-70. PubMed ID: 14498944 [TBL] [Abstract][Full Text] [Related]
75. The identification of the CF (cystic fibrosis) gene. Recent progress and new research strategies. Adv Exp Med Biol; 1991; 290():1-409. PubMed ID: 1950740 [No Abstract] [Full Text] [Related]
77. Application of the luminex LabMAP in rapid screening for mutations in the cystic fibrosis transmembrane conductance regulator gene: A pilot study. Dunbar SA; Jacobson JW Clin Chem; 2000 Sep; 46(9):1498-500. PubMed ID: 10973900 [No Abstract] [Full Text] [Related]
78. A new methodology for analysis of HLA-associated diseases? Clerget-Darpoux F; Goldin LR; Gershon ES Am J Hum Genet; 1983 Jan; 35(1):127-30. PubMed ID: 6823970 [No Abstract] [Full Text] [Related]
79. Equitable CF care as a basic human right. De Boeck K; Kerem E J Cyst Fibros; 2016 Nov; 15(6):703-704. PubMed ID: 27751793 [No Abstract] [Full Text] [Related]
80. CF end point commentary. Durmowicz AG J Cyst Fibros; 2016 Jul; 15(4):424. PubMed ID: 27324552 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]